BCLSI
TNGX icon

Bain Capital Life Sciences Investors’s Tango Therapeutics TNGX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-653,493
Closed -$5.79M – 22
2025
Q4 		$5.79M Sell
653,493
-2,058,515
-76% -$17.7M 0.44% 17
2025
Q3 		$22.8M Hold
2,712,008
– – 1.51% 11
2025
Q2 		$13.9M Hold
2,712,008
– – 1.74% 13
2025
Q1 		$3.72M Hold
2,712,008
– – 0.55% 17
2024
Q4 		$8.38M Hold
2,712,008
– – 0.99% 15
2024
Q3 		$20.9M Sell
2,712,008
-180,655
-6% -$1.72M 2.17% 9
2024
Q2 		$24.8M Hold
2,892,663
– – 2.72% 9
2024
Q1 		$23M Hold
2,892,663
– – 1.85% 14
2023
Q4 		$28.6M Hold
2,892,663
– – 2.75% 10
2023
Q3 		$32.6M Buy
2,892,663
+970,873
+51% +$5.92M 3.64% 8
2023
Q2 		$6.38M Hold
1,921,790
– – 0.66% 27
2023
Q1 		$7.59M Hold
1,921,790
– – 0.95% 26
2022
Q4 		$13.9M Hold
1,921,790
– – 1.56% 18
2022
Q3 		$6.96M Hold
1,921,790
– – 0.83% 25
2022
Q2 		$8.71M Hold
1,921,790
– – 1.02% 20
2022
Q1 		$14.6M Hold
1,921,790
– – 1.41% 18
2021
Q4 		$21M Hold
1,921,790
– – 1.67% 16
2021
Q3 		$24.8M Buy
1,921,790
+1,000,000
+108% +$12M 1.54% 16
2021
Q2 		$10.5M Buy
921,790
+421,790
+84% +$4.74M 0.69% 22
2021
Q1 		$5.56M Hold
500,000
– – 0.32% 26
2020
Q4 		$5.72M Hold
500,000
– – 0.36% 22
2020
Q3 		$5.18M Buy
+500,000
New +$5.11M 0.48% 21

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Bain Capital Life Sciences Investors's TNGX Position: Q1 2026 in Review

Bain Capital Life Sciences Investors sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 653,493 shares — an estimated $5.79M sold.

Bain Capital Life Sciences Investors first reported a position in TNGX in Q3 2020 and held it in 22 quarters. The position peaked at $32.6M in Q3 2023. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Bain Capital Life Sciences Investors reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 653,493 Tango Therapeutics shares in Q1 2026, an estimated $5.79M.
  • Bain Capital Life Sciences Investors first reported a position in Tango Therapeutics in Q3 2020 and held it in 22 quarters.
  • Bain Capital Life Sciences Investors's Tango Therapeutics position peaked at $32.6M in Q3 2023.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.